Clinical implications of VUS reclassification in a single-centre series from application of ACMG/AMP classification rules specified forBRCA1/2

医学遗传学 基因检测 遗传咨询 一致性(知识库) 医学 计算机科学 生物信息学 遗传学 内科学 生物 人工智能 基因
作者
Giovanni Innella,Simona Ferrari,Sara Miccoli,Elena Luppi,Cristina Fortuño,Michael T. Parsons,Amanda B. Spurdle,Daniela Turchetti
出处
期刊:Journal of Medical Genetics [BMJ]
卷期号:: jmg-109694 被引量:1
标识
DOI:10.1136/jmg-2023-109694
摘要

Background BRCA1/2 testing is crucial to guide clinical decisions in patients with hereditary breast/ovarian cancer, but detection of variants of uncertain significance (VUSs) prevents proper management of carriers. The ENIGMA (Evidence-based Network for the Interpretation of Germline Mutant Alleles) BRCA1/2 Variant Curation Expert Panel (VCEP) has recently developed BRCA1/2 variant classification guidelines consistent with ClinGen processes, specified against the ACMG/AMP (American College of Medical Genetics and Genomics/Association for Molecular-Pathology) classification framework. Methods The ClinGen-approved BRCA1/2- specified ACMG/AMP classification guidelines were applied to BRCA1/2 VUSs identified from 2011 to 2022 in a series of patients, retrieving information from the VCEP documentation, public databases, literature and ENIGMA unpublished data. Then, we critically re-evaluated carrier families based on new results and checked consistency of updated classification with main sources for clinical interpretation of BRCA1/2 variants. Results Among 166 VUSs detected in 231 index cases, 135 (81.3%) found in 197 index cases were classified by applying BRCA1/2- specified ACMG/AMP criteria: 128 (94.8%) as Benign/Likely Benign and 7 (5.2%) as Pathogenic/Likely Pathogenic. The average time from the first report as ‘VUS’ to classification using this approach was 49.4 months. Considering that 15 of these variants found in 64 families had already been internally reclassified prior to this work, this study provided 121 new reclassifications among the 151 (80.1%) remaining VUSs, relevant to 133/167 (79.6%) families. Conclusions These results demonstrated the effectiveness of new BRCA1/2 ACMG/AMP classification guidelines for VUS classification within a clinical cohort, and their important clinical impact. Furthermore, they suggested a cadence of no more than 3 years for regular review of VUSs, which however requires time, expertise and resources.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
程艳完成签到 ,获得积分10
刚刚
MINGHUI完成签到,获得积分10
1秒前
1秒前
子车半烟完成签到,获得积分10
1秒前
3秒前
淳于安筠完成签到,获得积分10
3秒前
雨晴完成签到,获得积分10
6秒前
jbq发布了新的文献求助10
6秒前
joshar完成签到,获得积分10
6秒前
7秒前
量子星尘发布了新的文献求助10
9秒前
blueblue完成签到,获得积分10
11秒前
落后秋烟完成签到,获得积分10
13秒前
大橙子发布了新的文献求助10
14秒前
LMY完成签到 ,获得积分10
14秒前
Betty完成签到 ,获得积分10
14秒前
NexusExplorer应助jbq采纳,获得10
15秒前
渔渔完成签到 ,获得积分10
15秒前
16秒前
Tangyartie完成签到 ,获得积分10
16秒前
skbkbe完成签到 ,获得积分10
17秒前
陈俊雷完成签到 ,获得积分0
18秒前
阿苗完成签到,获得积分10
19秒前
神勇的天问完成签到 ,获得积分10
20秒前
20秒前
advance完成签到,获得积分10
20秒前
李cc发布了新的文献求助10
21秒前
蒋念寒发布了新的文献求助10
22秒前
Sindy完成签到,获得积分10
22秒前
彭于晏应助HH采纳,获得30
24秒前
24秒前
朴实的小萱完成签到 ,获得积分10
25秒前
科研通AI5应助哭泣笑柳采纳,获得10
25秒前
25秒前
温暖的蚂蚁完成签到 ,获得积分10
28秒前
dhn123完成签到,获得积分10
28秒前
ccx完成签到,获得积分10
28秒前
29秒前
biofresh发布了新的文献求助30
29秒前
科研顺利完成签到,获得积分10
30秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038184
求助须知:如何正确求助?哪些是违规求助? 3575908
关于积分的说明 11373872
捐赠科研通 3305715
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022